NUP98 is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute biphenotypic leukemia trials with NUP98 alterations as inclusion criteria [4].

NUP98 is an inclusion criterion in 1 clinical trial for acute erythroid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and acute erythroid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute erythroid leukemia trials with NUP98 alterations as inclusion criteria [4].

NUP98 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute lymphoblastic leukemia trials with NUP98 alterations as inclusion criteria [4].

NUP98 is an inclusion criterion in 1 clinical trial for acute megakaryoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute megakaryoblastic leukemia trials with NUP98 alterations as inclusion criteria [4].

NUP98 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute myeloid leukemia trials with NUP98 alterations as inclusion criteria [4].

NUP98 is an inclusion criterion in 1 clinical trial for acute undifferentiated leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in acute undifferentiated leukemia trials with NUP98 alterations as inclusion criteria [4].

NUP98 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in chronic myeloid leukemia trials with NUP98 alterations as inclusion criteria [4].

NUP98 is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in hodgkin lymphoma trials with NUP98 alterations as inclusion criteria [4].

NUP98 is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in juvenile myelomonocytic leukemia trials with NUP98 alterations as inclusion criteria [4].

NUP98 is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in myelodysplastic syndromes trials with NUP98 alterations as inclusion criteria [4].

NUP98 is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in myeloid sarcoma trials with NUP98 alterations as inclusion criteria [4].

NUP98 is an inclusion criterion in 1 clinical trial for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in natural killer cell lymphoblastic leukemia/lymphoma trials with NUP98 alterations as inclusion criteria [4].

NUP98 is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in non-hodgkin lymphoma trials with NUP98 alterations as inclusion criteria [4].